Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
FLASH Radiation Reprograms Lipid Metabolism and Macrophage Immunity and Sensitizes Medulloblastoma to CAR T Cell Therapy
[Nature Cancer] Using a genetically engineered mouse model of medulloblastoma, researchers showed that FLASH radiation stimulated proinflammatory polarization in tumor macrophages.
Targeting the TRIM21-PD-1 Axis Potentiates Immune Checkpoint Blockade and CAR T Cell Therapy
[Molecular Therapy] Researchers reported that TRIM21 impaired CD8+ T cell activation and anti-tumor immunity. Mechanistically, TRIM21 catalyzed the K63-linked ubiquitination on PD-1 at K233, leading to stabilization of PD-1 through antagonizing its K48-linked ubiquitination and degradation.
Nature-Inspired Platform Nanotechnology for RNA Delivery to Myeloid Cells and Their Bone Marrow Progenitors
[Nature Nanotechnology] Researchers presented a nanotechnology platform based on natural lipoproteins, designed for delivering small interfering RNA, antisense oligonucleotides, and messenger RNA to myeloid cells and hematopoietic stem and progenitor cells in the bone marrow.
Novel Strategies to Manage CAR-T Cell Toxicity
[Nature Reviews Drug Discovery] Investigators summarize the current management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and review T cell- and myeloid cell-intrinsic druggable targets and cellular engineering strategies to develop safer CAR-T cells.
A Universal and Wide-Range Cytosine Base Editor via Domain-Inlaid and Fidelity-Optimized CRISPR-FrCas9
[Nature Communications] A series of iteratively improved cytosine base editors were constructed using the FrCas9 nickase with the unique protospacer adjacent motif palindromic structure to alleviate these challenges.
Vaccine-Induced T Cell Receptor T Cell Therapy Targeting a Glioblastoma Stemness Antigen
[Nature Communications] Researchers identified a therapeutic HLA-A*02-restricted protein tyrosine phosphatase receptor type Z1-reactive T cell receptor retrieved from a vaccinated glioblastoma patient.
Selective JAK2 Pathway Inhibition Enhances Anti-Leukemic Functionality in CD19 CAR-T Cells
[Cancer Immunology Immunotherapy] The authors explored the combinatorial use of a selective type II JAK2 inhibitor, CHZ868, with CD19 CAR-T cells, revealing a synergistic enhancement of anti-leukemic activity across B-cell tumor models irrespective of JAK2 mutational status.
Harnessing the Power of TCR-T Cell Therapy: A New Era in Cancer Immunotherapy
[Cancer Letters] The authors discuss the FDA's approval of "afami-cel," a first-in-class gene-modified autologous T cell therapy, for the treatment of specific solid tumor indications.
Results from First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor with Calibrated Signaling in Large B-Cell Lymphoma
[Journal of Clinical Oncology] In this first-in-human, Phase I, dose escalation and expansion clinical trial, patients with relapsed or refractory large B-cell lymphoma received 19(T2)28z-1XX CAR T cells at four dose levels.
Randomizing the Human Genome by Engineering Recombination Between Repeat Elements
[Science] The authors leveraged prime editing of the high-copy-number, long interspersed nuclear element-1 retrotransposon to engineer incorporation of thousands of Cre-recombinase sites into the genomes of two human cell lines.
Correcting a Pathogenic Mitochondrial DNA Mutation by Base Editing in Mice
[Science Translational Medicine] Researchers used a mitochondrial DddA-derived cytosine base editor to correct a mutation in the mitochondrial DNA encoding a mitochondrial transfer RNA alanine.
HIV Immune Evasin Nef Enhances Allogeneic CAR T Cell Potency
[Nature] To devise a strategy to protect allogeneic CAR T cells from host immune cells, scientists turned to lymphotropic viruses that have evolved integrated mechanisms for immune escape of virus-infected lymphocytes.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.